Abstract
Background
Recent studies implicate a pathophysiological role of tumor necrosis factor‐α (TNF‐α) in atherosclerosis, thus suggesting that serum TNF‐α levels may be one of the biomarkers for future cardiovascular events. However, which anthropometric, metabolic, and inflammatory variables could regulate circulating TNF‐α levels in humans is not fully understood. In this study, we examined the independent determinants of serum TNF‐α levels in a Japanese general population.
Hypothesis
Anthropometric, metabolic , and inflammatory variables could regulate TNF‐α.
Methods
A total of 213 Japanese subjects underwent a complete history, physical examination, and determination of blood chemistries, including TNF‐α levels. Univariate and multivariate analyses were applied for the determinants of TNF‐α levels.
Results
The average TNF‐α levels were 13.4 ± 0.81 pg/ml in males and 13.9 ± 4.5 pg/ml in females, respectively. Univariate analysis showed that TNF‐α levels were associated with age (P = 0.007), body mass index (P = 0.034), waist circumference (<0.001), high‐density lipoprotein cholesterol (HDL‐C; inversely, P < 0.001), triglycerides (P < 0.001), creatinine (P < 0.001), uric acids (P < 0.001), insulin (P = 0.008), homeostasis model assessment of insulin resistance (HOMA‐IR; P = 0.015), high sensitivity C‐reactive protein (hs‐CRP; P < 0.001), and fibrinogen (P = 0.009). By the use of multiple stepwise regression analyses, HDL‐C (inversely, P < 0.001) and hs‐CRP (P < 0.001) remained significant and were independently related to TNF‐α levels (R 2 = 0.153).
Conclusions
The present study is the first demonstration that besides hs‐CRP, a decreased HDL‐C level is an independent determinant of circulating TNF‐α in the Japanese general population. Elevation of TNF‐α may partly explain the increased risk of cardiovascular events in patients with low HDL‐C levels. Copyright © 2009 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (98.8 KB).
References
- 1. Manitovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J 1992; 6: 2591–2599. [DOI] [PubMed] [Google Scholar]
- 2. Bruunsgaard H, Skinhoj P, Pedersen AN, Schroll M, Pedersen BK. Ageing, tumor necrosis factor‐α (TNF‐α) and atherosclerosis. Clin Exp Immunol 2000; 121: 255–260. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Yamagishi S, Inagaki Y, Abe R, et al. Nifedipine inhibits apoptotic cell death of cultured endothelial cells induced by tumor necrosis factor‐α. Drugs Exp Clin Res 2003; 29: 141–145. [PubMed] [Google Scholar]
- 4. Yamagishi S, Inagaki Y, Kikuchi S. Nifedipine inhibits tumor necrosis factor‐α ‐induced monocyte chemoattractant protein‐1 overexpression by blocking NADPH oxidase‐mediated reactive oxygen species generation. Drugs Exp Clin Res 2003; 29: 147–152. [PubMed] [Google Scholar]
- 5. Yamagishi S, Nakamura K, Matsui T. Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. Curr Med Chem 2008; 15: 172–177. [DOI] [PubMed] [Google Scholar]
- 6. Skoog T, Dichtl W, Boquist S, et al. Plasma tumor necrosis factor‐alpha and early carotid atherosclerosis in healthy middle‐aged men. Eur Heart J 2002; 23: 376–383. [DOI] [PubMed] [Google Scholar]
- 7. Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor‐alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149–2153. [DOI] [PubMed] [Google Scholar]
- 8. Enomoto M, Adachi H, Yamagishi S, et al. Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans. Metabolism 2006; 55: 912–917. [DOI] [PubMed] [Google Scholar]
- 9. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor‐α inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994; 91: 4854–4858. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor‐α: direct role in obesity‐linked insulin resistance. Science 1993; 259: 87–91. [DOI] [PubMed] [Google Scholar]
- 11. Matsushita K, Yatsuya H, Tamakoshi K, et al. Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 2006; 26: 871–876. [DOI] [PubMed] [Google Scholar]
- 12. Moon YS, Kim DH, Song DK. Serum tumor necrosis factor‐α levels and components of the metabolic syndrome in obese adolescents. Metabolism 2004; 53: 863–867. [DOI] [PubMed] [Google Scholar]
- 13. Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H. Relation between plasma tumor necrosis factor‐α and insulin sensitivity in elderly men with non‐insulin‐dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1998; 18: 11991–1201. [DOI] [PubMed] [Google Scholar]
- 14. Borst SE. The role of TNF‐α in insulin resistance. Endocrine 2004; 23: 177–182. [DOI] [PubMed] [Google Scholar]
- 15. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004; 15: 2792–2800. [DOI] [PubMed] [Google Scholar]
- 16. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor‐α in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409–2415. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89: 763–771. [DOI] [PubMed] [Google Scholar]
- 18. Burger D, Dayer JM. High‐density lipoprotein‐associated apolipoprotein A‐I: the missing link between infection and chronic inflammation? Autoimmun Rev 2002; 1: 111–117. [DOI] [PubMed] [Google Scholar]
- 19. Calabresi L, Rossoni G, Gomaraschi M, et al. High‐density lipoproteins protect isolated rat hearts from ischemia‐reperfusion injury by reducing cardiac tumor necrosis factor‐α content and enhancing prostaglandin release. Circ Res. 2003; 92: 330–337. [DOI] [PubMed] [Google Scholar]
- 20. Klimov AN, Gurevich VS, Nikiforova AA, et al. Antioxidative activity of high density lipoproteins in vivo. Atherosclerosis 1993; 100: 13–18. [DOI] [PubMed] [Google Scholar]
- 21. Kontush A, de Faria EC, Chantepie S, Chapman MJ. A normotriglyceridemic, low HDL‐cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 2005; 182: 277–285. [DOI] [PubMed] [Google Scholar]